Search

Your search keyword '"Hepatitis C, Chronic drug therapy"' showing total 15,327 results

Search Constraints

Start Over You searched for: Descriptor "Hepatitis C, Chronic drug therapy" Remove constraint Descriptor: "Hepatitis C, Chronic drug therapy"
15,327 results on '"Hepatitis C, Chronic drug therapy"'

Search Results

1. Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination.

2. Benchmarking of an Intervention Aiming at the Micro-Elimination of Hepatitis C in Vulnerable Populations in Perpignan, France, to Inform Scale-Up and Elimination on the French Territory.

3. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C.

4. Rescue therapy with Sofosbuvir /Velpatasvir/ Voxilaprevir in a patient infected with Hepatitis C virus multidrug resistant variant-a much needed option for DAA-treatment failures in Pakistan? A case-report.

5. High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam.

6. Multiparametric liver assessment in patients successfully treated for hepatitis C: a 4-year follow-up.

7. Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.

8. HCV-HIV co-infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece.

9. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis.

10. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis.

11. Impact of Treatment with Direct Antivirals on Coagulation Parameters in Patients with Hepatitis C Virus-Related Liver Cirrhosis and Sustained Virological Response.

12. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.

13. Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study.

14. Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients.

15. Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C Shows Liver Fibrosis Regression on Three Noninvasive Tests: A Puerto Rican Cohort.

16. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan.

17. External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients.

18. Impact of DAA Treatment for HCV on Hepatocellular Carcinoma in a Predominately African American Population.

19. Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C).

20. Sofosbuvir (+) daclatasvir (+) ribavirin in Egyptian patients with hepatitis C virus: Therapeutic outcomes and the prognostic role of natural killer cells.

22. Natural History and Management of Hepatitis C in Children: 25 Years Experience of a Reference Center in Northern Italy.

23. Kidney transplant recipient with history of HIV, HBV, and past HCV infection.

24. The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study.

25. Patient profiled data for treatment decision-making: valuable as an add-on to hepatitis C clinical guidelines?

26. Prospective Assessment of Serum Lipid Alterations in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals: Insights Six Months Post Sustained Virological Response.

27. Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C.

28. 'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment.

29. Predictive Value of Interleukin 6 and Interleukin 8 in Response to Treatment of Hepatitis C Virus.

30. Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.

32. [Hepatitis C: From diagnosis to global virus elimination].

33. Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals.

34. Modified by the Innovative Drugs and Strategies-Pattern of Selected Indications for Pediatric Liver Transplantation.

35. Hepatocellular carcinoma after direct-acting antivirals for hepatitis C is associated with KIR-HLA types predicting weak NK cell-mediated immunity.

36. Improved outcomes of liver resection for hepatitis C-related hepatocellular carcinoma after the introduction of direct-acting antiviral therapy.

37. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.

38. Administering a Soda Beverage With the Hepatitis C Treatment Sofosbuvir/Velpatasvir and the Proton-Pump Inhibitor Pantoprazole: A Case Report.

39. MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.

40. Measures of insulin resistance and beta cell function before and after treatment of HCV infection.

41. EASL position paper on clinical follow-up after HCV cure.

42. Metformin as adjuvant treatment in hepatitis C virus infections and associated complications.

43. Better prognosis of HCV patients diagnosed and treated with an automatic alert system.

44. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.

45. IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C.

46. Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment.

47. Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.

48. Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment.

49. Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.

50. Hepatitis C treatment outcome among people in prison: The SToP-C study.

Catalog

Books, media, physical & digital resources